Agenus Inc.has strengthened its cash position to operate through 2013, giving the immunotherapeutics developer more time to advance its proprietary pipeline and partnered adjuvant QS-21 Stimulon. The company announced it had significantly increased its cash balance March 5 through several measures, including an amended partnership agreement with GlaxoSmithKline PLC.
The company raised $9 million through the expanded agreement with GSK, $6.25 million through a license of “noncore technologies” to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?